Huuhtanen R L, Blomqvist C P, Wiklund T A, Böhling T O, Virolainen M J, Tukiainen E J, Tribukait B, Andersson L C
Helsinki University Central Hospital, Department of Oncology, Finland.
Br J Cancer. 1999 Feb;79(5-6):945-51. doi: 10.1038/sj.bjc.6690151.
Immunohistochemically determined Ki-67 scores and flow cytometrically determined S-phase fractions were successfully evaluated from the primary tumours of 123 patients with soft-tissue sarcoma. All patients had either limb or superficial trunk tumours. Ki-67 score correlated strongly with ploidy, S-phase fraction and grade. Ki-67 did not correlate with the size of the primary tumour. When analysed as a continuous variable, Ki-67 was a stronger predictor of both metastasis-free survival and disease-specific overall survival (P = 0.003 and 0.04 respectively) than was the S-phase fraction (P = 0.06 and 0.07 respectively). We tested the relevance of different cut-point values by dividing the whole material into two parts at every 10% (e.g. 10% of patients vs. the remaining 90%, 20% vs. 80%, etc.). We counted the relative risk and confidence interval at all these cut-off points. Ki-67 had good prognostic discriminating power irrespective of the cut-point value, but S-phase fraction lost its prognostic power at higher cut-point values. In conclusion, we found that Ki-67 is a useful prognostic tool in the treatment of soft-tissue sarcoma patients irrespective of the cut-point value. S-phase fraction can be used at lower cut-point values.
通过免疫组织化学方法测定了123例软组织肉瘤患者原发肿瘤的Ki-67评分,并通过流式细胞术测定了S期分数。所有患者均患有肢体或躯干浅表肿瘤。Ki-67评分与倍性、S期分数和分级密切相关。Ki-67与原发肿瘤大小无关。当作为连续变量进行分析时,与S期分数相比(分别为P = 0.06和0.07),Ki-67是无转移生存期和疾病特异性总生存期更强的预测指标(分别为P = 0.003和0.04)。我们通过将整个材料每10%分为两部分(例如,10%的患者与其余90%,20%与80%等)来测试不同切点值的相关性。我们计算了所有这些切点处的相对风险和置信区间。无论切点值如何,Ki-67都具有良好的预后判别能力,但S期分数在较高切点值时失去了其预后能力。总之,我们发现无论切点值如何,Ki-67都是治疗软组织肉瘤患者的有用预后工具。S期分数可用于较低的切点值。